Journal: bioRxiv

Article Title: Activation of the endoplasmic reticulum unfolded protein response reverses an inflammation-like response to cytoplasmic DNA

doi: 10.1101/440883

Figure Lengend Snippet: a. A cartoon showing the approach to intestinal injection. Ph, pharynx; Int I, Int II, intestinal rings I and II; arrow indicates the approximate location of the injection. b. Plot of the pharyngeal pumping rates of wt and nuc-1 worms injected with purified ECO85 genomic DNA. c. Plot of the pharyngeal pumping rates of uninjected wt and nuc-1 worms over the first 72 hours after reaching the young adult stage (24 h after L4). d. Plot of the pharyngeal pumping rates of wt and nuc-1 worms injected the fluorescent co-injection marker in the same buffer (rhodamine-dextran) without DNA. c. Plot of the pharyngeal pumping rates of uninjected wt and nuc-1 worms over the first 72 hours after reaching the young adult stage (24 h after L4). d. Plot of the pharyngeal pumping rates of the same strains injected with synthetic CpG-containing oligoribodeoxynucleotide (ODN 2395). f. ( top ) Comparison of the sequences of ODN 2395 and the control, ODN 5328. Red bases show the CpG sequences in ODN 2395 and blue bases highlight the same positions in the control ODN 5328. ( bottom ) Plot of the pharyngeal pumping rates of nuc-1 worms injected with ODN 2395 or ODN 5328. Each plot shows the mean ± S.D at each time point. The statistical significance of the differences in the trends between the control and experimental groups was assessed using two-way ANOVA (n.s. P > 0.05, ** 0.01 > P > 0.001, *** P < 0.001).

Article Snippet: DNA from the pathogenic E. coli strain ECO85 was purified using the Puregene Core Kit A (Qiagen, Hilden, Germany) and injected at a concentration of 8 μg/μl and the synthetic CpG oligodeoxyribonucleotide ODN 2395 (Miltenyi Biotec, Bergisch Gladbach, Germany) was injected at a concentration of 100 ng/μl.

Techniques: Injection, Purification, Marker, Comparison

Journal: Vaccines

Article Title: Comparative Evaluation of Mucosal Adjuvants for Intranasal Immunization with a Recombinant RSV Prefusion F Protein

doi: 10.3390/vaccines14020186

Figure Lengend Snippet: The immune response levels and protective evaluation induced by different doses of CpG-ODN adjuvant in mice: ( A ) Experimental groups and immunization regimen; ( B ) Serum antigen-specific IgG levels after immunization; ( C ) Serum neutralizing antibody titers after immunization; ( D ) Antigen-specific IgA levels in nasal lavage fluid after challenge; ( E ) Body weight changes after challenge; ( F ) Ct values for lung viral load after challenge; ( G ) Total lung pathology score after challenge; ( H ) Antigen-specific IgA in lung homogenates after challenge; (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns, not significant).

Article Snippet: Type C CpG-ODN (ODN 2395, VacciGradeTM), PMA plus ionomycin, and mouse lymphocyte separation medium were purchased from Dakewe Biotech Co., Ltd.

Techniques: Adjuvant